Novo Nordisk ( NVO 6.12%) stock, maker of the blockbuster GLP-1 agonist weight-loss drugs Ozempic and Wegovy, jumped a lucky ...

Novo Nordisk has launched a new late-stage trial for its experimental next-generation obesity drug candidate, CagriSema, as ...

Key Takeaways Novo Nordisk stock rose on Tuesday after the Financial Times reported that an activist investor is building a ...

Activist hedge fund Parvus Asset Management is building a stake in Novo Nordisk , after the company lost its first mover ...

The European Medicines Agency's safety committee has concluded that a potentially dangerous eye condition is a very rare side ...

Denmark-based multinational pharmaceutical company Novo Nordisk will be making available in the Philippines within this year ...

Novo Nordisk’s drugs are being linked to an eye condition that can cause vision loss, while health tech companies made CNBC’s ...

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market. Read why I ...

A media report stated that an activist investor is accumulating a stake in the Wegovy maker. Wegovy and Ozempic maker Novo ...

Wegovy maker Novo Nordisk has hired the start-up Deep Apple Therapeutics to develop small molecules as its next weight-loss ...

Novo Nordisk (NVO) stock gains as the company launches a new Phase 3 trial for its next-gen weight loss drug CagriSema after ...